[Therapy with NO donors-antiatherogenic and antioxidant actions].
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology; D002248:Carbon Monoxide / Q000097:blood; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy; D004730:Endothelium, Vascular / Q000187:drug effects; D004790:Enzyme Induction / Q000187:drug effects; D005293:Ferritins / Q000097:blood; D006419:Heme Oxygenase (Decyclizing) / Q000097:blood; D051547:Heme Oxygenase-1; D006801:Humans; D008565:Membrane Proteins; D020030:Nitric Oxide Donors / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects; D010417:Pentaerythritol Tetranitrate / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011817:Rabbits; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000975:Antioxidants; D008565:Membrane Proteins; D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; D010417:Pentaerythritol Tetranitrate; C100210:pentrinitrol; D002248:Carbon Monoxide; D005293:Ferritins; C496541:HMOX1 protein, human; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1
Therapie mit NO-Donatoren. Desiderat einer antiarteriosklerotischen und antioxidativen Therapie.